Download PDF
J Neurol Surg A Cent Eur Neurosurg 2022; 83(04): 351-360
DOI: 10.1055/s-0041-1735515
Original Article

IDH Wild-type Glioblastoma Presenting with Seizure: Clinical Specificity, and Oncologic and Surgical Outcomes

Alessandro Pesce
1   “Santa Maria Goretti” Hospital, Latina, Italy
,
Daniele Armocida 
2   Division of Neurosurgery, Department of Human Neurosciences, “Sapienza” University, Rome, Italy
,
Francesco Paglia
2   Division of Neurosurgery, Department of Human Neurosciences, “Sapienza” University, Rome, Italy
,
Mauro Palmieri
2   Division of Neurosurgery, Department of Human Neurosciences, “Sapienza” University, Rome, Italy
,
Alessandro Frati
2   Division of Neurosurgery, Department of Human Neurosciences, “Sapienza” University, Rome, Italy
3   IRCCS “Neuromed” Pozzilli (IS), Italy
,
Giancarlo D'Andrea
4   Department of Neurosurgery, “Spaziani” Hospital, Frosinone, Italy
,
Maurizio Salvati
3   IRCCS “Neuromed” Pozzilli (IS), Italy
5   Department of Mental and Neurological, Dental and Sensory Organs Health, Tor Vergata University, Rome Italy
,
Antonio Santoro
1   “Santa Maria Goretti” Hospital, Latina, Italy
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Glioblastoma (GBM) is the most common and aggressive primary brain neoplasia in adults. Seizure is a common manifestation in GBM. Up to 25 to 60% of patients with GBM have seizures. We aim to summarize all the relevant clinical, surgical, radiologic, and molecular features of a cohort of patients suffering from GBM-related epilepsy and measure the outcome, to understand the possible existence of a clinical/phenotypical specificity of this subgroup of patients.

Methods We retrospectively analyzed a cohort of 177 patients affected by isocitrate dehydrogenase wild-type (IDH-WT) GBM; 49 patients presented seizure at onset (SaO) and 128 were seizure free (SF). We investigated the relationship between seizures and other prognostic factors of GBMs.

Results A statistically significant association between the location of the lesions in the parietal lobe and seizures was observed. The left side was more commonly affected. Interestingly, there was a statistical relationship between tumors involving the subventricular zone (SVZ) and SaO patients. The tumors were also smaller on average at diagnosis, and generalized SaOs were associated with longer overall survival.

Conclusions The typical patient with IDH-WT GBM with SaO is a young (<55 year) male without a history of headache. The lesion is typically small to medium in size and located in the temporoparietal dominant lobe, with a high tendency to involve the SVZ.

Keywords

seizure - glioblastoma - EGFR - p53 - survival - brain tumor - epilepsy


Publication History

Received: 14 September 2020

Accepted: 09 March 2021

Article published online:
18 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Perry A, Wesseling P. Histologic classification of gliomas. Handb Clin Neurol 2016; 134: 71-95
    CrossrefPubMedGoogle Scholar
  • 2 Wirsching H-G, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol 2016; 134: 381-397
    CrossrefPubMedGoogle Scholar
  • 3 Filbin MG, Suvà ML. Gliomas genomics and epigenomics: arriving at the start and knowing it for the first time. Annu Rev Pathol 2016; 11: 497-521
    CrossrefPubMedGoogle Scholar
  • 4 Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro-oncol 2009; 11 (03) 330-339
    CrossrefPubMedGoogle Scholar
  • 5 Ertürk Çetin Ö, İşler C, Uzan M, Özkara Ç. Epilepsy-related brain tumors. Seizure 2017; 44: 93-97
    CrossrefPubMedGoogle Scholar
  • 6 Englot DJ, Berger MS, Chang EF, Garcia PA. Characteristics and treatment of seizures in patients with high-grade glioma: a review. Neurosurg Clin N Am 2012; 23 (02) 227-235 vii–viii
    CrossrefPubMedGoogle Scholar
  • 7 Kerkhof M, Dielemans JCM, van Breemen MS. et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro-oncol 2013; 15 (07) 961-967
    CrossrefPubMedGoogle Scholar
  • 8 Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia 2013; 54 (Suppl. 09) 12-17
    CrossrefPubMedGoogle Scholar
  • 9 Chaichana KL, Parker SL, Olivi A, Quiñones-Hinojosa A. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 2009; 111 (02) 282-292
    CrossrefPubMedGoogle Scholar
  • 10 Henker C, Kriesen T, Scherer M. et al. Association between tumor compartment volumes, the incidence of pretreatment seizures, and statin-mediated protective effects in glioblastoma. Neurosurgery 2019; 85 (04) E722-E729
    CrossrefPubMedGoogle Scholar
  • 11 Feyissa AM, Worrell GA, Tatum WO. et al. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. Seizure 2019; 69: 283-289
    CrossrefPubMedGoogle Scholar
  • 12 Tönjes M, Barbus S, Park YJ. et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 2013; 19 (07) 901-908
    CrossrefPubMedGoogle Scholar
  • 13 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
    Google Scholar
  • 14 Beghi E, Giussani G, Grosso S. et al. Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia 2013; 54 (Suppl. 07) 2-12
    CrossrefPubMedGoogle Scholar
  • 15 Fisher RS, Cross JH, French JA. et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017; 58 (04) 522-530
    CrossrefPubMedGoogle Scholar
  • 16 Armocida D, Frati A, Salvati M, Santoro A, Pesce A. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter progression free survival? A clinical and Molecular analytic investigation. Clin Neurol Neurosurg 2020; 198: 106126
    CrossrefPubMedGoogle Scholar
  • 17 Armocida D, Pesce A, Di Giammarco F, Frati A, Salvati M, Santoro A. Histological, molecular, clinical and outcomes characteristics of multiple lesion glioblastoma. A retrospective monocentric study and review of literature. Neurocirugia (Astur) 2020
    PubMedGoogle Scholar
  • 18 Malakhov N, Lee A, Garay E, Becker DJ, Schreiber D. Patterns of care and outcomes for glioblastoma in patients with poor performance status. J Clin Neurosci 2018; 52: 66-70
    CrossrefPubMedGoogle Scholar
  • 19 Adeberg S, Bostel T, König L, Welzel T, Debus J, Combs SE. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival?. Radiat Oncol 2014; 9 (01) 95
    CrossrefPubMedGoogle Scholar
  • 20 Altmann C, Keller S, Schmidt MHH. The role of SVZ stem cells in glioblastoma. Cancers (Basel) 2019; 11 (04) E448
    CrossrefPubMedGoogle Scholar
  • 21 Pesce A, Palmieri M, Armocida D, Frati A, Miscusi M, Raco A. Spinal myxopapillary ependymoma: the Sapienza University experience and comprehensive literature review concerning the clinical course of 1602 patients. World Neurosurg 2019; 129: 245-253
    CrossrefPubMedGoogle Scholar
  • 22 Yao F, Wang J, Yao J, Hang F, Lei X, Cao Y. Three-dimensional image reconstruction with free open-source OsiriX software in video-assisted thoracoscopic lobectomy and segmentectomy. Int J Surg 2017; 39: 16-22
    CrossrefPubMedGoogle Scholar
  • 23 Armocida D, Pesce A, Frati A, Miscusi M, Paglia F, Raco A. Pneumoventricle of unknown origin: a personal experience and literature review of a clinical enigma. World Neurosurg 2019; 122: 661-664
    CrossrefPubMedGoogle Scholar
  • 24 Frati A, Pesce A, D'Andrea G. et al. A purely functional imaging based approach for transcortical resection of lesion involving the dominant atrium: towards safer, imaging-guided, tailored cortico-leucotomies. J Clin Neurosci 2018; 50: 252-261
    CrossrefPubMedGoogle Scholar
  • 25 Raco A, Pesce A, Fraschetti F. et al. Risk of postoperative performance status worsening after resection of lesions involving the motor pathway: a multinomial logistic regression model. J Neurol Surg A Cent Eur Neurosurg 2018; 79 (06) 453-463
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Frati A, Pesce A, Palmieri M. et al. Hypnosis-aided awake surgery for the management of intrinsic brain tumors versus standard awake-asleep-awake protocol: a preliminary, promising experience. World Neurosurg 2019; 121: e882-e891
    CrossrefPubMedGoogle Scholar
  • 27 van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6 (05) 421-430
    CrossrefPubMedGoogle Scholar
  • 28 Goldstein ED, Feyissa AM. Brain tumor related-epilepsy. Neurol Neurochir Pol 2018; 52 (04) 436-447
    CrossrefPubMedGoogle Scholar
  • 29 Huberfeld G, Vecht CJ. Seizures and gliomas: towards a single therapeutic approach. Nat Rev Neurol 2016; 12 (04) 204-216
    CrossrefPubMedGoogle Scholar
  • 30 Yang P, Liang T, Zhang C. et al. Clinicopathological factors predictive of postoperative seizures in patients with gliomas. Seizure 2016; 35: 93-99
    CrossrefPubMedGoogle Scholar
  • 31 Frati A, Pesce A, Palmieri M, Celniku M, Raco A, Salvati M. Surgical treatment of the septuagenarian patients suffering from brain metastases: a large retrospective observational analytic cohort-comparison study. World Neurosurg 2018; 114: e565-e572
    CrossrefPubMedGoogle Scholar
  • 32 Carlson C, Dugan P, Kirsch HE, Friedman D. EPGP Investigators. Sex differences in seizure types and symptoms. Epilepsy Behav 2014; 41: 103-108
    CrossrefPubMedGoogle Scholar
  • 33 Isoardo G, Morra I, Chiarle G. et al. Different aquaporin-4 expression in glioblastoma multiforme patients with and without seizures. Mol Med 2012; 18: 1147-1151
    CrossrefPubMedGoogle Scholar
  • 34 Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004; 79 (12) 1489-1494
    CrossrefPubMedGoogle Scholar
  • 35 Armocida D, Pesce A, Di Giammarco F, Frati A, Santoro A, Salvati M. Long term survival in patients suffering from glio-blastoma multiforme: a single-center observational cohort study. Diagnostics (Basel) 2019; 9 (04) 209
    CrossrefPubMedGoogle Scholar
  • 36 Armocida D, Pesce A, Frati A, Santoro A, Salvati M. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?. J Neurooncol 2020; 146 (02) 275-284
    CrossrefPubMedGoogle Scholar
  • 37 Lee JW, Wen PY, Hurwitz S. et al. Morphological characteristics of brain tumors causing seizures. Arch Neurol 2010; 67 (03) 336-342
    PubMedGoogle Scholar
  • 38 Salvati M, Pesce A, Palmieri M, Floriana Brunetto GM, Santoro A, Frati A. The role and real effect of an iterative surgical approach for the management of recurrent high-grade glioma: an observational analytic cohort study. World Neurosurg 2019; 124: e480-e488
    CrossrefPubMedGoogle Scholar
  • 39 Cayuela N, Simó M, Majós C. et al. Seizure-susceptible brain regions in glioblastoma: identification of patients at risk. Eur J Neurol 2018; 25 (02) 387-394
    CrossrefPubMedGoogle Scholar
  • 40 Kahlenberg CA, Fadul CE, Roberts DW. et al. Seizure prognosis of patients with low-grade tumors. Seizure 2012; 21 (07) 540-545
    CrossrefPubMedGoogle Scholar
  • 41 Wick W, Weller M, van den Bent M. et al. MGMT testing: the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10 (07) 372-385
    CrossrefPubMedGoogle Scholar
  • 42 Marucci G, de Biase D, Visani M. et al. Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia. Ann Clin Transl Neurol 2014; 1 (02) 130-134
    CrossrefPubMedGoogle Scholar
  • 43 Liubinas SV, D'Abaco GM, Moffat BM. et al. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Epilepsia 2014; 55 (09) 1438-1443
    CrossrefPubMedGoogle Scholar
  • 44 Junqueira D, Brusque AM, Porciúncula LO. et al. In vitro effects of D-2-hydroxyglutaric acid on glutamate binding, uptake and release in cerebral cortex of rats. J Neurol Sci 2004; 217 (02) 189-194
    CrossrefPubMedGoogle Scholar
  • 45 Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol 2018; 12 (01) 3-20
    CrossrefPubMedGoogle Scholar
  • 46 Yang P, You G, Zhang W. et al. Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas: a report of 198 patients from China. Seizure 2014; 23 (10) 844-851
    CrossrefPubMedGoogle Scholar
  • 47 Glantz MJ, Cole BF, Forsyth PA. et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54 (10) 1886-1893
    CrossrefPubMedGoogle Scholar
  • 48 Dührsen L, Sauvigny T, Ricklefs FL. et al. Seizures as presenting symptom in patients with glioblastoma. Epilepsia 2019; 60 (01) 149-154 Dec.
    CrossrefPubMedGoogle Scholar
  • 49 Berendsen S, Varkila M, Kroonen J. et al. Prognostic relevance of epilepsy at presentation in glioblastoma patients. Neuro-oncol 2016; 18 (05) 700-706
    CrossrefPubMedGoogle Scholar